Syros Pharmaceuticals Stock Today
| SYRS Stock | USD 1.96 0.04 2.08% |
Performance0 of 100
| Odds Of DistressOver 80
|
Syros Pharmaceuticals is selling for under 1.96 as of the 27th of September 2024; that is 2.08 percent increase since the beginning of the trading day. The stock's lowest day price was 1.86. Syros Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Syros Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of June 2024 and ending today, the 27th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of June 2016 | Category Healthcare | Classification Health Care |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. The company has 26.81 M outstanding shares of which 1.1 M shares are at this time shorted by private and institutional investors with about 1.96 trading days to cover. More on Syros Pharmaceuticals
Moving against Syros Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Syros Stock Highlights
| President CEO | Conley Chee | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSyros Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Syros Pharmaceuticals' financial leverage. It provides some insight into what part of Syros Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Syros Pharmaceuticals (SYRS) is traded on NASDAQ Exchange in USA. It is located in 35 CambridgePark Drive, Cambridge, MA, United States, 02140 and employs 68 people. Syros Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 51.47 M. Syros Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 26.81 M outstanding shares of which 1.1 M shares are at this time shorted by private and institutional investors with about 1.96 trading days to cover.
Syros Pharmaceuticals currently holds about 244.48 M in cash with (109.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Syros Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationSyros Pharmaceuticals shows a total of 26.81 Million outstanding shares. The majority of Syros Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Syros Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Syros Pharmaceuticals. Please pay attention to any change in the institutional holdings of Syros Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Syros Ownership Details
Syros Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blue Owl Capital Holdings Lp | 2024-06-30 | 340.9 K | |
| Walleye Trading Advisors, Llc | 2024-06-30 | 285.8 K | |
| Ubs O'connor Llc | 2024-06-30 | 278.1 K | |
| Exoduspoint Capital Management, Lp | 2024-06-30 | 263.7 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 262.4 K | |
| Blackrock Inc | 2024-06-30 | 259.2 K | |
| Omega Fund Management Llc | 2024-06-30 | 251.3 K | |
| Geode Capital Management, Llc | 2024-06-30 | 226.1 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 160.4 K | |
| Bain Capital Life Sciences Investors, Llc | 2024-06-30 | 2.7 M | |
| Artal Group S A | 2024-06-30 | 2.5 M |
Syros Pharmaceuticals Historical Income Statement
Syros Stock Against Markets
Syros Pharmaceuticals Corporate Management
| James MD | Founder | Profile | |
| Lisa Roberts | Vice Resources | Profile | |
| JD Esq | Chief Development | Profile | |
| Eric Olson | Chief Scientific Officer | Profile | |
| Jason Haas | Chief Officer | Profile |
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.